Ocugen(NASDAQ) OCGN

Market Cap$402.84M

Since IPO (2019)-58%

5 Year-82%

1 Year+16%

1 Month-29%

$1.27

+6.3%

+0.08Today

Ocugen last closing stock price
Metric	Price	Date
Last close	USD 1.19	2026-07-29

Ocugen stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-7.75%	USD 1.29	2026-07-22
1 month	-28.74%	USD 1.67	2026-06-29
3 month	-31.21%	USD 1.73	2026-04-30
Year to date	-11.85%	USD 1.35	2025-12-31
1 year	+15.53%	USD 1.03	2025-07-29
3 year	+99.66%	USD 0.60	2023-07-28
5 year	-82.27%	USD 6.71	2021-07-30
Since inception	-58.25%	USD 2.85	2019-09-30

Ocugen Financials at a Glance

Market Cap

$402.84M

Revenue (TTM)

$4.47M

Net Income (TTM)

-$71.67M

EPS (TTM)

-$0.23

P/E Ratio

-5.14

Dividend

$0.00

Beta (Volatility)

2.04 (High)

Dividend

$0.00

Beta (Volatility)

2.04 (High)

Price

$1.27

Volume

3,505,045

Open

$1.22

Price

$1.27

Volume

3,505,045

Open

$1.22

Previous Close

$1.26

Daily Range

$1.19 - $1.27

52-Week Range

$0.93 - $2.73

Estimated Earnings Date

Jul 30, 2026

Dividend

$0.00

Beta (Volatility)

2.04 (High)

Price

$1.27

Volume

3,505,045

Open

$1.22

Previous Close

$1.26

Daily Range

$1.19 - $1.27

52-Week Range

$0.93 - $2.73

Estimated Earnings Date

Jul 30, 2026

OCGN News

Why Ocugen Stock Zoomed 12% Higher Today

Eric VolkmanSep 15, 2025

Ocugen (OCGN) Q2 Revenue Jumps 20%

Motley Fool Markets TeamAug 1, 2025

1 Stock That More Than Doubled This Year That I Wouldn't Touch With a 10-Foot Pole

Prosper Junior BakinyMay 24, 2024

3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall Street

Sean WilliamsJan 23, 2023

Why Shares of Ocugen Jumped Thursday

James HalleyDec 29, 2022

Page 1

OCGN: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Ocugen

Ocugen develops gene therapies to fix blindness and vision loss. These treatments help people with rare eye diseases. The company also builds vaccines and cartilage repairs.

Tools for Eyes and Beyond

Modifier Gene Therapy: Treatments like OCU400 and OCU410 designed to address many genetic causes of blindness with one product.
Regenerative Cell Therapy: Technology called NeoCart that uses a patient's own cells to grow new cartilage for knee repairs.
Fusion Protein Biologics: Product candidate OCU200 aimed at treating vision complications caused by diabetes and age-related changes.
Inhaled Vaccine Platform: Needle-free vaccines for COVID-19 and the flu delivered through inhalation to generate local immunity.

Strategic Partnerships and Global Deals

Partnered with Kwangdong Pharmaceutical in September 2025 to develop and sell eye therapies in South Korea.
Acquired exclusive rights from Washington University in 2022 to develop a mucosal COVID-19 vaccine.
Shifted assets for the NeoCart cartilage repair program to the wholly owned subsidiary OrthoCellix in 2025.
Secured selection by the National Institute of Allergy and Infectious Diseases (NIAID) Project NextGen in October 2023 for clinical trial support.

How Ocugen Differentiates Itself

Ocugen utilizes a modifier gene therapy platform designed to treat various blindness diseases using a gene-agnostic approach. Its operations rely on a network of global partners and academic institutions for specialized manufacturing and research technology.

Financial Performance for 2025

Revenue fell to $-193,000 in Q4 2025, down 125.3% from $764,000 in Q4 2024.
Operating loss was $17 million in Q4 2025, worsening 22.8% from the previous year.
Net loss reached $17.7 million in Q4 2025, a 27.6% worsening compared to Q4 2024.
Operating cash flow was negative $14 million in Q4 2025, worsening 34.7% year-over-year.

Bottom Line

Ocugen has transitioned from early research into a clinical-stage developer with multiple late-stage programs for vision and respiratory health. Its expansion into vaccines and cell therapy provides a broader operational base beyond its original focus on inherited retinal diseases.

AI Generated • May 5, 2026

Industry

Biotechnology

Sector

Health Care

Employees

116

CEO

Shankar Musunuri, PhD, MBA

Website

www.ocugen.com

Headquarters

Malvern, PA 19355, US

OCGN Financials

Key Financial Metrics (TTM)

Gross Margin

100.00%

Operating Margin

-1483.85%

Net Income Margin

-1605.22%

Return on Equity

-127987.50%

Return on Capital

-299.91%

Return on Assets

-125.95%

Earnings Yield

-19.46%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$402.84M

Shares Outstanding

338.52M

Volume

3.51M

Avg. Volume

7.61M

Financials (TTM)

Gross Profit

$4.47M

Operating Income

-$66.25M

EBITDA

-$63.06M

Operating Cash Flow

-$59.40M

Capital Expenditure

-$175.00K

Free Cash Flow

-$59.58M

Cash & ST Invst.

$31.86M

Total Debt

$33.30M

Ocugen Performance Analysis

Ocugen annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 2,488,000	N/A
2023	2023-12-31	USD 6,036,000	142.6%
2024	2024-12-31	USD 4,055,000	-32.8%
2025	2025-12-31	USD 4,413,000	8.8%

Ocugen sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	-7.3%
Q3	2025-09-30	27.6%
Q4	2025-12-31	-111.0%
Q1	2026-03-31	894.3%

Ocugen annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.40	35.1%
2023	2023-12-31	USD -0.26	-36.2%
2024	2024-12-31	USD -0.20	-22.8%
2025	2025-12-31	USD -0.23	13.4%

Ocugen sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q2	2025-06-30	4.0%
Q3	2025-09-30	-30.7%
Q4	2025-12-31	14.1%
Q1	2026-03-31	-5.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q1 2026YOY CHG

Revenue

$1.53M

+3.5%

Gross Profit

$1.53M

+3.5%

Gross Margin

100.00%

N/A

Market Cap

$402.84M

N/A

Market Cap/Employee

$3.47M

N/A

Employees

116

N/A

Net Income

-$19.18M

-24.9%

EBITDA

-$17.27M

-27.6%

Quarterly Fundamentals

Name

Q1 2026YOY CHG

Total Cash

$31.86M

-15.7%

Total Debt

$33.30M

+4.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$27.44M

-11.7%

Short Term Debt

$5.86M

+695.5%

Return on Assets

-1.26%

N/A

Return on Invested Capital

-1.83%

N/A

Free Cash Flow

-$21.80M

-12.5%

Operating Cash Flow

-$21.79M

-12.6%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CMPXCompass Therapeutics, Inc.

CMPXCompass Therapeutics, Inc.$1.94+0.00%

NMRANeumora Therapeutics, Inc. Common Stock

NMRANeumora Therapeutics, Inc. Common Stock$1.65+0.00%

NGNENeurogene Inc.

NGNENeurogene Inc.$33.60-0.16%

FULCFulcrum Therapeutics, Inc.

FULCFulcrum Therapeutics, Inc.$3.72+2.76%

ADCTADC Therapeutics S.A.

ADCTADC Therapeutics S.A.$1.11+0.91%

OMEROmeros Corporation

OMEROmeros Corporation$11.93+2.23%

RAPTRAPT Therapeutics, Inc.

RAPTRAPT Therapeutics, Inc.$58.01+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

INTCIntel

INTCIntel$91.13+0.11%

NVDANvidia

NVDANvidia$195.04+0.03%

MSFTMicrosoft

MSFTMicrosoft$451.10+0.16%

NOKNokia

NOKNokia$9.09+0.08%

AMZNAmazon

AMZNAmazon$235.50+0.04%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$7.21+0.07%

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares

MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares$26.97+0.37%

Questions About OCGN

What is the current price of Ocugen?

Ocugen is trading at $1.26 per share.

What is the 52-week range for Ocugen?

Over the past 52 weeks, Ocugen has traded between $0.93 and $2.73.

How much debt does Ocugen have?

As of the most recent reporting period, Ocugen reported total debt of $33.30M.

How much cash does Ocugen have on hand?

Ocugen reported $31.86M in cash and cash equivalents in its most recent financial results.

What is Ocugen’s dividend yield?

Ocugen does not currently have a dividend yield.

Ocugen(NASDAQ) OCGN

Ocugen Financials at a Glance

OCGN News

Why Ocugen Stock Zoomed 12% Higher Today

Ocugen (OCGN) Q2 Revenue Jumps 20%

1 Stock That More Than Doubled This Year That I Wouldn't Touch With a 10-Foot Pole

Can Ocugen Stock Keep Churning Higher?

Why Ocugen Stock Eked Out a Win Today

1 Reason to Buy Ocugen in 2023 and 2 Reasons to Sell

3 Under-the-Radar Stocks With 590% to 772% Upside in 2023, According to Wall Street

Why Shares of Ocugen Jumped Thursday

OCGN: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Ocugen

Tools for Eyes and Beyond

Strategic Partnerships and Global Deals

How Ocugen Differentiates Itself

Financial Performance for 2025

Bottom Line

OCGN Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Ocugen Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About OCGN

What is the current price of Ocugen?

What is the 52-week range for Ocugen?

How much debt does Ocugen have?

How much cash does Ocugen have on hand?

What is Ocugen’s dividend yield?

Premium Investing Services